Antibiotice (BSE:ATB) Other Current Payables: lei22.7 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:ATB Antibiotice SA BSE:ATB
75 GF Score
Price lei2.18
GF Value lei2.20
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Antibiotice Other Current Payables?

Antibiotice BSE:ATB -0.23% 75 Other Current Payables is lei22.7 Mil as of Mar. 2026. GuruFocus rates BSE:ATB with a GF Score™ of 75/100 and a GF Value™ of lei2.20 (Fairly Valued). The stock has 6 warning signs investors should review.

Antibiotice's Other Current Payables for the quarter that ended in Mar. 2026 was lei22.7 Mil.

Antibiotice's quarterly Other Current Payables increased from Sep. 2025 (lei39.0 Mil) to Dec. 2025 (lei39.6 Mil) but then declined from Dec. 2025 (lei39.6 Mil) to Mar. 2026 (lei22.7 Mil).

Antibiotice's annual Other Current Payables increased from Dec. 2023 (lei44.0 Mil) to Dec. 2024 (lei55.8 Mil) but then declined from Dec. 2024 (lei55.8 Mil) to Dec. 2025 (lei39.6 Mil).

Antibiotice Other Current Payables Related Terms

Antibiotice Other Current Payables Historical Data

* Premium members only.

The historical data trend for Antibiotice's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibiotice Other Current Payables Chart

Antibiotice Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.42 16.53 44.01 55.79 39.61

Antibiotice Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.84 28.94 39.02 39.61 22.72
BSE:ATB
75GF Score
Antibiotice SA BSE:ATB
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibiotice Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of lei22.7 Mil mean?
Antibiotice (BSE:ATB) has a Other Current Payables of lei22.7 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Antibiotice and its competitors.
Is Antibiotice's Other Current Payables too high?
Antibiotice's current Other Current Payables is lei22.7 Mil. Overall, Antibiotice has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Antibiotice's Other Current Payables compare to ZTS and UTHR?
Antibiotice's Other Current Payables of lei22.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Antibiotice and its competitors. Antibiotice's current Other Current Payables is lei22.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibiotice stock overvalued right now?
Based on GuruFocus' analysis, Antibiotice (BSE:ATB) is currently considered Fairly Valued. The stock's GF Value™ is lei2.20, compared to a current price of lei2.18 — trading 0.9% below its estimated fair value. The current Other Current Payables is lei22.7 Mil. Antibiotice's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Antibiotice (BSE:ATB), the current Other Current Payables is lei22.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antibiotice (BSE:ATB) Overvalued in 2026?

Based on GuruFocus' analysis, Antibiotice stock appears to be undervalued. The current stock price of lei2.18 is trading 0.9% below its estimated GF Value™ of lei2.20. GuruFocus considers Antibiotice to be Fairly Valued.

Key valuation signals for BSE:ATB:

  • Other Current Payables: lei22.7 Mil
  • GF Value™: lei2.20 vs. price of lei2.18 (0.9% below fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the BSE:ATB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antibiotice Business Description

Address 1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
75GF Score

Get the complete analysis for BSE:ATB

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei2.18
Price
lei2.20
GF Value